Inhibikase Therapeutics, Inc. (IKT)
NASDAQ: IKT · Real-Time Price · USD
1.380
0.00 (0.00%)
At close: Nov 18, 2026, 4:00 PM EST
1.390
+0.010 (0.72%)
After-hours: Nov 18, 2026, 4:20 PM EST
Inhibikase Therapeutics Stock Forecast
Stock Price Forecast
According to 10 analysts polled by S&P Global, Inhibikase Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $5.55. The average 1-year stock price forecast is 302.17% higher than the current stock price, while the lowest is $1.50 (+8.70%) and the highest is $8.00 (+479.71%).
Price Target: $5.55 (+302.17%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Inhibikase Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 8 | 8 | 8 | 8 | 7 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 9 | 9 | 9 | 10 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Bank of America Securities | Bank of America Securities | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Nov 16, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $8 | Buy | Reiterates | $8 | +479.71% | Nov 13, 2026 |
| Maxim Group | Maxim Group | Buy Maintains $8 | Buy | Maintains | $8 | +479.71% | Nov 12, 2026 |
| Oppenheimer | Oppenheimer | Buy Maintains $5 | Buy | Maintains | $5 | +262.32% | Nov 11, 2026 |
| Chardan Capital | Chardan Capital | Hold Initiates $1.5 | Hold | Initiates | $1.5 | +8.70% | Oct 13, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.41
EPS Next Year
-0.40
from -0.41
EPS and Forward PE are based on non-GAAP adjusted numbers.